4D pharma has released additional positive data from its completed Phase II trial of LBP Blautix in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhoea (IBS-D). The data has been presented in a poster session at Digestive Disease Week (DDW), on May 22, 2021, by Professor Eamonn Quigley, Head of Gastroenterology and […]